KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Deferred Taxes (2024 - 2025)

Historic Deferred Taxes for Alnylam Pharmaceuticals (ALNY) over the last 4 years, with Q3 2025 value amounting to $5.6 million.

  • Alnylam Pharmaceuticals' Deferred Taxes rose 353435.58% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$82.4 million, marking a year-over-year decrease of 81633.06%. This contributed to the annual value of -$106.8 million for FY2024, which is 1487363.25% down from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Deferred Taxes of $5.6 million as of Q3 2025, which was up 353435.58% from $9.7 million recorded in Q2 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Deferred Taxes peaked at $9.7 million during Q2 2025, and registered a low of -$107.4 million during Q4 2024.